Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial - Report - MDSpire

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • By

  • Chloe Stanley

  • Ritwika Mallik

  • Nausheen Hamid

  • Friedrich C. Jassil

  • Victoria Reuven

  • Tapiwa Ruwona

  • Samuel J. Dicken

  • Sulmaaz Qamar

  • Benjamin Norton

  • Helen Kingett

  • Andrea Pucci

  • Cormac Magee

  • David Boniface

  • Rachel L. Batterham

  • Kalpana Devalia

  • Jessica Mok

  • Mohamed Elkalaawy

  • John Loy

  • Andrew Jenkinson

  • Haris Markakis

  • Marco Adamo

  • Alanna Brown

  • Janine Makaronidis

  • May 22, 2026

  • 0 min

Share

Comparison of Semaglutide and Placebo in Patients with Inadequate Weight Loss Following Bariatric Surgery

Overview

This study evaluates the efficacy of semaglutide 2.4 mg in patients with inadequate weight loss after bariatric surgery compared to placebo.

Background

Obesity is a global health crisis, contributing to millions of deaths annually and associated with various comorbidities. While metabolic and bariatric surgery (MBS) is effective for long-term weight loss, approximately 20% of patients experience suboptimal results.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Semaglutide 2.4 mg has shown superior weight-reducing efficacy compared to liraglutide 3.0 mg in non-diabetic adults.
  • In the BARI-OPTIMISE trial, liraglutide 3.0 mg resulted in a weight loss of 9.4% at 24 weeks compared to 1.1% with placebo.
  • GLP-1 receptor agonists are associated with improved glycemic control and weight loss in patients with inadequate responses to MBS.

Clinical Implications

The findings indicate a need for further investigation into pharmacological options for patients experiencing inadequate weight loss after bariatric surgery.

Conclusion

Further investigation into the efficacy and safety of semaglutide for patients with inadequate weight loss following bariatric surgery is warranted.

Related Resources & Content

  1. Obesity Surgery, 2025 -- Semaglutide as an Adjunct Therapy in Patients Receiving Intragastric Balloon Treatment for Weight Loss
  2. conexiant, 2025 -- Dual Therapy Boosts Weight Loss in Trial
  3. Obesity Surgery, 2025 -- Efficacy of Adjuvant Semaglutide After Bariatric Metabolic Surgery
  4. American Society for Metabolic and Bariatric Surgery Statement, 2026 -- Treatment options for patients with non-response and weight recurrence after MBS
  5. International Journal of Obesity, 2025 -- Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis
  6. conexiant — Semaglutide Tested in Alcohol Use Disorder
  7. American Society for Metabolic and Bariatric Surgery Statement on the Treatment options for patients with non-response and weight recurrence after Metabolic and Bariatric Surgery - ScienceDirect
  8. Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis | International Journal of Obesity
  9. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial | Trials | JAMA Surgery | JAMA Network

Original Source(s)

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • by Chloe Stanley, Ritwika Mallik, Nausheen Hamid, Friedrich C. Jassil, Victoria Reuven, Tapiwa Ruwona, Samuel J. Dicken, Sulmaaz Qamar, Benjamin Norton, Helen Kingett, Andrea Pucci, Cormac Magee, David Boniface, Rachel L. Batterham, Kalpana Devalia, Jessica Mok, Mohamed Elkalaawy, John Loy, Andrew Jenkinson, Haris Markakis, Marco Adamo, Alanna Brown, Janine Makaronidis

  • May 22, 2026

Related Content

Epicardial fat area as an independent predictor of atrial fibrillation occurrence and severity

A Digital Toolkit for Weight Loss Maintenance in European Adults (NoHoW): 2×2 Factorial Randomized Controlled Trial

NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases